touchMDT for touchONCOLOGY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?
touchMDT for touchONCOLOGY
What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?
Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights.
The multidisciplinary team
Medical oncologist – Dr Jacob Sands
Dana-Farber Cancer Institute, Boston, MA, USA
Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands
This touchPODCAST is for HCPs outside…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.